A traditional Chinese medicine composition for treating psoriasis, a preparation method and application thereof

Abstract

The application discloses a traditional Chinese medicine composition for treating psoriasis and a preparation method and application thereof, relates to the technical field of traditional Chinese medicines, and comprises ephedra, cassia twig, red peony root, giant knotweed, artemisia annua and oldenlandia diffusa. Compared with Kai Xuan Jie Du recipe, the traditional Chinese medicine composition disclosed by the application omits Coptis chinensis, indigo and gentiana scabra, is more concise in prescription, and has more advantages in improving psoriasis-like skin lesions of model mice.

Description

Technical Field

[0001] This invention belongs to the field of traditional Chinese medicine technology, and relates to a traditional Chinese medicine composition for treating psoriasis, its preparation method and application. Background Technology

[0002] Psoriasis, also widely known as "cowhide rash," is a common polygenic hereditary skin disease, often manifesting as localized or widespread scaly erythematous plaques or patches. The exact cause of psoriasis is unclear, but it is believed to be a result of the combined effects of genetic and environmental factors. There are several types of psoriasis, the most common being plaque psoriasis, followed by psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis. Symptoms of psoriasis are diverse, primarily including red plaques on the skin, usually covered with silvery-white scales, itching, burning or pain, dryness, cracking, and even bleeding of the skin. Some patients may also experience joint pain, swelling, and nail abnormalities. Current treatment methods include medication, phototherapy, and traditional Chinese medicine. Although a complete cure is not currently possible, active treatment can significantly reduce skin lesions or promote healing, prevent serious complications, and improve patients' quality of life.

[0003] Qin Yeping, Dai Dan, Xiao Xue, Song Ping. Kaixuan Jiedu Formula Improves Skin Lesions in Imiquimod-Induced Psoriasis-Like Mice by Regulating S1P Levels [J]. Journal of Jiangsu University (Medical Edition), 2023, 33(2): 118-125. This paper discloses that Kaixuan Jiedu Formula can improve the symptoms and signs of psoriasis in mice in multiple ways, such as improving splenomegaly, thymic atrophy, capillary hyperplasia, reducing the degree of epidermal hyperplasia, repairing the skin barrier, and reducing the expression of local inflammatory factors. Furthermore, this drug can regulate not only S1P expression but also the expression level of S1PR at the mRNA level. The S1P / S1PR pathway is very likely a potential target of Kaixuan Jiedu Formula, and S1P / S1PR plays an important role in inflammatory signaling pathways, skin cell proliferation, and the skin barrier. However, this paper only discloses the composition of Kaixuan Jiedu Formula, without disclosing the drug ratio or optimizing the drug ratio.

[0004] In view of this, in order to overcome the shortcomings of the prior art, the present invention provides a traditional Chinese medicine composition for treating psoriasis, its preparation method and application. The traditional Chinese medicine composition disclosed in the present invention can be used to prepare drugs for treating psoriasis. Summary of the Invention

[0005] The purpose of this invention is to overcome the shortcomings of previous research and provide a traditional Chinese medicine composition for treating psoriasis, its preparation method and application, so as to give full play to the efficacy of traditional Chinese medicine and effectively solve the problem of medication for the treatment of psoriasis.

[0006] To achieve the above objectives, the technical solution adopted by the present invention is as follows:

[0007] On the one hand, the present invention provides a traditional Chinese medicine composition for treating psoriasis, which is composed of ephedra, cinnamon twig, red peony root, Japanese knotweed, artemisia annua, and oldenlandia diffusa.

[0008] Preferably, the traditional Chinese medicine composition comprises, by weight, 1-12 parts of ephedra, 3-18 parts of cinnamon twig, 3-18 parts of red peony root, 5-20 parts of Japanese knotweed, 5-40 parts of artemisia annua, and 5-40 parts of oldenlandia diffusa.

[0009] More preferably, the traditional Chinese medicine composition comprises, by weight, 6 parts ephedra, 9 parts cinnamon twig, 9 parts red peony root, 10 parts Japanese knotweed, 20 parts artemisia annua, and 20 parts oldenlandia diffusa.

[0010] In another aspect, the present invention provides a method for preparing the above-mentioned traditional Chinese medicine composition, characterized by comprising the following steps: taking ephedra, cinnamon twig, red peony root, Japanese knotweed, artemisia annua, and oldenlandia diffusa and grinding them into powder.

[0011] In another aspect, the present invention provides a medicine whose active ingredients include the above-mentioned traditional Chinese medicine composition.

[0012] The drug can be prepared into dosage forms such as pills, capsules, granules, oral liquids, powders, tablets, lozenges, and sugar lozenges. For different dosage forms, a suitable drug carrier in this field can be selected.

[0013] The drug carrier used can be solid, liquid, or gaseous. Examples of solid carriers include lactose, kaolin, sucrose, talc, gelatin, agar, pectin, gum arabic, magnesium stearate, and stearic acid. Examples of liquid carriers include syrup, peanut oil, olive oil, and water. Examples of gaseous carriers include carbon dioxide and nitrogen.

[0014] In preparing compositions for oral dosage forms, any convenient pharmaceutical medium can be used. For example, water, ethanol, oils, alcohols, flavoring agents, preservatives, coloring agents, etc., can be used to form oral liquid dosage forms, such as suspensions and solutions; while carriers, such as starch, sugars, microcrystalline cellulose, diluents, granulators, emulsifiers, lubricants, binders, and disintegrants, can be used to form oral solid dosage forms, such as powders, capsules, and tablets. Tablets and capsules are preferred oral dosage units using solid pharmaceutical carriers due to their ease of administration. Tablets can be coated using standard aqueous or non-aqueous techniques.

[0015] Tablets containing the traditional Chinese medicine composition of the present invention can be prepared by compression or molding, and one or more excipients or adjuvants may be used. The active ingredient can be compressed in a free-flowing form (e.g., powder or granules) in a suitable machine, optionally mixed with binders, lubricants, inert diluents, surfactants, or dispersants. Molded tablets can be molded in a suitable machine, i.e., a mixture of powdered compounds moistened with an inert liquid diluent. Each tablet preferably contains about 0.05 mg to about 5 g of active ingredient, and each sachet or capsule preferably contains about 0.05 mg to about 5 g of active ingredient. For example, a formulation intended for oral administration to humans may contain about 0.5 mg to about 5 g of active drug, mixed with a suitable and convenient carrier material, which may comprise about 5% to 95% of the total composition. Unit dosage forms typically contain about 1 mg to about 2 g of active ingredient, typically in doses of 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg, or 1000 mg.

[0016] The pharmaceutical compositions of this invention suitable for parenteral administration can be prepared as aqueous solutions or suspensions of the active compound. Suitable surfactants, such as hydroxypropyl cellulose, may be included. Dispersions can also be prepared in mixtures of glycerol, liquid polyethylene glycol, and their oils. Furthermore, preservatives may be added to prevent harmful microbial growth.

[0017] The medicaments of the present invention can be in forms suitable for topical use, such as aerosols, creams, ointments, lotions, powders, or the like. Furthermore, the compositions can be in suitable forms for transdermal drug delivery devices. These formulations can be prepared using the traditional Chinese medicine compositions of the present invention through conventional processing methods. For example, a cream or ointment with a desired consistency can be prepared by mixing a hydrophilic material and water, and about 5 wt% to about 10 wt% of the compound.

[0018] The medicament of the present invention can be in a form suitable for rectal administration, wherein the carrier is solid. It is preferable to formulate the mixture into a single-dose suppository. Suitable carriers include cocoa butter and other materials commonly used in the art. Suppositories can be made by first forming a mixture containing a softened or melted carrier, followed by cooling and shaping in a mold.

[0019] In addition to the carrier components described above, the pharmaceutical formulations may include (if applicable) one or more additional carrier components, such as diluents, buffers, flavoring agents, binders, surfactants, thickeners, lubricants, preservatives (including antioxidants), etc. Furthermore, other excipients may be added, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, etc., colorants, and flavoring agents, etc., to make the formulation isotonic with the blood of the intended receptor. Components containing the traditional Chinese medicine composition of this invention can also be prepared in powder or concentrated form.

[0020] Preferably, the pharmaceutical preparation is an oral pharmaceutical preparation.

[0021] More preferably, the oral drug preparation is any one of decoction, pill, tablet, capsule, powder, granule, or oral liquid.

[0022] Finally, this invention provides the application of the above-mentioned traditional Chinese medicine composition in the preparation of drugs for treating psoriasis.

[0023] Preferably, the psoriasis is selected from any one of psoriasis vulgaris, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis.

[0024] More preferably, the psoriasis is psoriasis vulgaris.

[0025] Preferably, the symptoms of psoriasis include:

[0026] (1) Red patches appear on the skin, covered with silvery-white scales;

[0027] (2) Itching, burning, or pain in the skin;

[0028] (3) Dry, cracked, or bleeding skin;

[0029] (4) Scalp dandruff appears;

[0030] (5) Fingernails and / or toenails are “thimble-like” or dotted pits, onycholysis, or hyperkeratosis of the nail bed;

[0031] (6) Joint swelling.

[0032] More preferably, the symptoms of psoriasis include:

[0033] (1) Red patches appear on the skin, covered with silvery-white scales;

[0034] (2) Itching, burning, or pain in the skin;

[0035] (3) Dry, cracked or bleeding skin.

[0036] Compared with the prior art, the present invention has the following beneficial effects:

[0037] Compared with the Kaixuan Detoxification Formula (composed of Artemisia annua, Polygonum cuspidatum, Hedyotis diffusa, Coptis chinensis, Ephedra sinica, Cinnamomum cassia, Indigo naturalis, and Gentiana scabra), the traditional Chinese medicine composition disclosed in this invention omits Coptis chinensis, Indigo naturalis, and Gentiana scabra, making the prescription more concise and more advantageous in improving psoriasis-like skin lesions in model mice. Attached Figure Description

[0038] Figure 1 The effects of Examples 1-3 and Comparative Examples 1-3 on the skin lesion manifestations of model mice.

[0039] Figure 2 PASI scores of dorsal skin lesions in mice of the control group, model group, and Examples 1-3 groups were measured on day 6. ** P<0.01; *** P<0.001.

[0040] Figure 3 On day 6, the PASI scores of dorsal skin lesions in mice of the control group, model group, Example 1 group, and Comparative Examples 1-3 groups were measured. ** P<0.01; *** P<0.001.

[0041] Figure 4 The effects of Examples 1-3 and Comparative Examples 1-3 on the pathological manifestations of skin lesions in psoriasis model mice were investigated. Detailed Implementation

[0042] The following non-limiting embodiments are intended to enable those skilled in the art to gain a more comprehensive understanding of the present invention, but do not limit the invention in any way. The following content is merely an exemplary description of the scope of protection claimed in this application. Those skilled in the art can make various changes and modifications to the invention based on the disclosed content, and such changes should also fall within the scope of protection claimed in this application.

[0043] The present invention will be further described below by way of specific embodiments. Unless otherwise specified, all pharmaceuticals used in the embodiments of the present invention are obtained through conventional commercial channels.

[0044] Ephedra is the herbaceous stem of plants such as Ephedra sinica, Ephedra equisetifolia, or Ephedra intermedium, belonging to the Ephedraceae family.

[0045] Cinnamon twigs are the tender branches of the cinnamon tree, a plant in the Lauraceae family.

[0046] Red peony root is the dried root of the plant *Paeonia lactiflora* or *Paeonia veitchii*, belonging to the Ranunculaceae family.

[0047] Japanese knotweed is the dried rhizome and root of Polygonum cuspidatum Sieb. et Zucc., a plant belonging to the Polygonaceae family.

[0048] Artemisia annua L., a plant in the Asteraceae family, is the dried aerial part of the plant.

[0049] Oldenlandia diffusa, a plant belonging to the Rubiaceae family and the Oldenlandia genus, is a species of Oldenlandia diffusa.

[0050] The whole herb of Hedyotis diffusa Willd. [Oldenlandia diffusa (Willd.) Roxb.].

[0051] Example 1

[0052] The formula is as follows: 6 parts ephedra, 9 parts cinnamon twig, 9 parts red peony root, 10 parts Japanese knotweed, 20 parts artemisia annua, and 20 parts oldenlandia diffusa.

[0053] Preparation method: Take the prescribed amount of medicinal materials and grind them into powder.

[0054] Example 2

[0055] The formula is as follows: 1 part ephedra, 3 parts cinnamon twig, 18 parts red peony root, 20 parts Japanese knotweed, 40 parts artemisia annua, and 40 parts oldenlandia diffusa.

[0056] The preparation method is the same as in Example 1.

[0057] Example 3

[0058] The formula is as follows: 12 parts ephedra, 18 parts cinnamon twig, 3 parts red peony root, 5 parts Japanese knotweed, 5 parts artemisia annua, and 5 parts oldenlandia diffusa.

[0059] The preparation method is the same as in Example 1.

[0060] Comparative Example 1

[0061] The formula is as follows: Ephedra 1 part, Cinnamon Twig 3 parts, Polygonum Cuspidatum 20 parts, Artemisia annua 40 parts, Hedyotis diffusa 40 parts, Coptis chinensis 6 parts, Indigo Naturalis 3 parts, Gentiana scabra 9 parts. This formula is referenced in the literature (Qin Yeping, Dai Dan, Xiao Xue, et al. Kaixuan Jiedu Formula improves the skin lesions of imiquimod-induced psoriasis-like mice by regulating S1P level [J]. Journal of Jiangsu University: Medical Edition, 2023, 33(2):118-125.DOI:10.13312 / j.issn.1671-7783.y230038.).

[0062] The preparation method is the same as in Example 1.

[0063] Comparative Example 2

[0064] The formula is as follows: 6 parts ephedra and 9 parts cinnamon twig.

[0065] The preparation method is the same as in Example 1.

[0066] Comparative Example 3

[0067] The formula is as follows: 9 parts red peony root, 10 parts Japanese knotweed, 20 parts artemisia annua, and 20 parts oldenlandia diffusa.

[0068] The preparation method is the same as in Example 1.

[0069] Result detection

[0070] 1. Experimental Materials and Methods

[0071] 1.1 Laboratory Animals

[0072] Specific pathogen-free (SPF) grade C57BL / 6J mice, male, 6-8 weeks old, weighing 18-22 g, a total of 48 mice, were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd., license number: SCXK (Beijing) 2021-0006. The mice were housed under SPF conditions in the animal room of Guang'anmen Hospital, China Academy of Chinese Medical Sciences. All were given standard ordinary feed, the environmental humidity was 55±5%, the temperature was controlled at 22-25°C, and the lighting time was 12 h / day. They were cage-raised, 6 in each cage, a total of 8 cages, and had free access to food and water. The experimental protocol was approved by the Experimental Animal Ethics Committee of Guang'anmen Hospital, China Academy of Chinese Medical Sciences (approval number: IACUC-GAMH-2021-021). All experimental animal protocols were operated in accordance with the guidelines approved by the Animal Ethics Committee.

[0073] 1.2. Experimental drugs

[0074] The examples and comparative examples were provided by the Pharmacy of Guang'anmen Hospital, China Academy of Chinese Medical Sciences; Imiquimod Cream (company: 3M HealthCare limited, import drug registration certificate number: H20160079, specification: 12.5 mg / 250 mg).

[0075] 1.3. Main experimental reagents

[0076] Table 1 Main experimental reagents

[0077]

[0078]

[0079] 1.4. Experimental methods

[0080] 1.4.1. Establishment of psoriasis mouse model

[0081] After all the C57BL / 6J mice in the model group were adaptively raised for one week, they were prepared for modeling. One day before modeling, the hair on the back of the mice was shaved with a hair clipper to form an exposed area of about 2 cm×3 cm. Then, the exposed area was smeared and covered with depilatory cream. After the depilatory cream stayed on the back of the mice for 90 s, the back depilatory cream and the remaining hair were removed with a tissue paper dipped in warm water to fully expose the back skin of the mice. After the modeling started, 62.5 mg of imiquimod cream was smeared on the bare skin at 9:00 every day, once a day for 5 consecutive days. The mice in the blank group were smeared with 62.5 mg of vaseline on the back at the same time as a control.

[0082] 1.4.2. Grouping and administration

[0083] Gavage administration started 4 h after modeling. Conversion was carried out according to the human-mouse body surface area (1:12.3) in "Pharmacological Experiment Methodology", that is, 30.34 g of crude drug / kg. The specific grouping is as follows:

[0084] ① Control group: 62.5mg of petroleum jelly was applied to the back and administered via gavage with 0.2mL of distilled water;

[0085] ② Model group: 62.5mg imiquimod cream was applied to the back and administered via gavage with 0.2mL distilled water;

[0086] ③ Example 1 group: 62.5mg imiquimod cream was applied to the back and 30.34g of the crude drug prepared in Example 1 was administered by gavage at a volume of 0.2mL.

[0087] ④ Example 2 group: 62.5mg imiquimod cream was applied to the back and 30.34g of the crude drug prepared in Example 2 was administered by gavage at a volume of 0.2mL.

[0088] ⑤ Example 3 group: 62.5mg imiquimod cream was applied to the back and 30.34g of the crude drug prepared in Example 3 was administered by gavage at a volume of 0.2mL.

[0089] ⑥ Comparative Example 1: 62.5 mg imiquimod cream was applied to the back and 30.34 g of the crude drug prepared in Comparative Example 1 was administered by gavage at a volume of 0.2 mL.

[0090] ⑦ Comparative Example 2: 62.5 mg imiquimod cream was applied to the back and 30.34 g of the crude drug prepared in Comparative Example 2 was administered by gavage at a volume of 0.2 mL.

[0091] ⑧ Comparative Example 3: 62.5 mg imiquimod cream was applied to the back and 30.34 g of the crude drug prepared in Comparative Example 3 was administered by gavage at a volume of 0.2 mL.

[0092] Six mice were administered the drug once a day by gavage for five consecutive days. The mice were weighed and their skin lesions were scored using the PASI system before applying imiquimod cream each day. The morphology of the mice's back skin was also recorded by taking photos under consistent lighting and photographic equipment.

[0093] 1.4.3 Sample Collection and Preservation

[0094] After establishing the mouse model and intervention on day 5, the feed was removed, and the mice were starved. On day 6, at 8:00 AM, samples were collected. Mice were anesthetized by intraperitoneal injection of a 0.3% sodium pentobarbital solution prepared with physiological saline at a dose of 0.2 mL / 10 g. After anesthesia, the whiskers were trimmed, the eyeballs were removed with forceps, and blood was collected using serum separation gel coagulation tubes. The collected test tubes were then stored at room temperature.

[0095] After blood collection from the mice, the skin was placed on a pre-sterilized foam board. Skin was then excised from the back using surgical scissors and rinsed in PBS solution. The subcutaneous tissue side of the skin was placed face up on white filter paper, and the subcutaneous vascularization was photographed to record the findings. The skin tissue was divided into four portions. One portion was attached to filter paper and immersed in neutral formalin fixative to prevent tissue curling. The other three portions were placed in labeled cryovials, flash-frozen in liquid nitrogen, and then stored at -80°C for later use.

[0096] 1.4.4 PASI score for skin lesions

[0097] On days 1-6, before modeling, the changes in skin lesions on the back of mice were photographed and recorded using fixed equipment and relatively consistent lighting conditions. At the same time, the PASI scoring criteria were used to score the erythema (0-4 points), scaling (0-4 points), and infiltration degree (0-4 points) of the mouse skin lesions. The sum of the three scores was the PASI score.

[0098] 1.4.5 Preparation and sectioning of histopathological paraffin blocks

[0099] Tissues fixed for 72 hours or more were removed from the fixative, and the tissue portions to be observed were cut with a scalpel and placed in a marked tissue embedding cassette. The tissues were then sequentially immersed in 75% ethanol for 2 hours, 85% ethanol for 30 minutes, 95% ethanol for 2 hours (with a solution change), 95% ethanol for 2 hours, anhydrous ethanol for 2 hours (with a solution change), and anhydrous ethanol for 2 hours (with a solution change). The tissues were then cleared by immersion in xylene for 1.5 hours (with a solution change), xylene for 1.5 hours (with a solution change), and xylene for 45 minutes (with a solution change). The paraffin melting tank of the tissue embedding machine was started in advance and set to 62°C to melt the paraffin. The dehydrated and cleared tissues were then immersed in paraffin for 3 hours.

[0100] After paraffin infiltration is completed, start the cold stage of the embedding machine, prepare the pathological tissue paraffin block embedding mold in advance, open the embedding box, take out the tissue that has been infiltrated with paraffin, drop 1 / 4 of the paraffin into the mold, use tweezers to place the tissue to be observed face up in the mold, wait for the paraffin in the mold to solidify slightly, quickly drop the mold to fill it with paraffin and cover the bottom of the embedding box, transfer it to the cold stage, wait for the paraffin block to solidify, transfer it from the cold stage to the room temperature laboratory operating table for demolding, and the preparation of the tissue pathology paraffin block is completed.

[0101] Start the slide warmer in advance, setting the water temperature to 55℃. Take the prepared paraffin block and fix it in the paraffin microtome. Turn on the humidifier and aim it at the paraffin block. Initially set it to coarse trimming at 20μm / cut, and once you reach the tissue, set it to fine trimming, with skin tissue at 4.5μm. After sectioning, use tweezers to spread the tissue slide in the slide warmer until the tissue is fully expanded and wrinkle-free. Use a regular glass slide or a high-adhesion glass slide to retrieve the slide and let it air dry overnight.

[0102] 1.4.6 Eosin-Hematoxylin (HE) Staining

[0103] The slide baking machine was set to 60℃ for 1 hour. After the paraffin was fully melted, xylene was added sequentially for 10 minutes, followed by (replacement) xylene for 5 minutes, (replacement) xylene for 5 minutes, anhydrous ethanol for 10 minutes, (replacement) anhydrous ethanol for 5 minutes, 95% ethanol for 5 minutes, 80% ethanol for 5 minutes, 70% ethanol for 5 minutes, and then washed with tap water for dewaxing. The dewaxed tissue slides were then stained with hematoxylin for 15 minutes, and excess staining solution was washed away with tap water. Differentiation was performed using 1% hydrochloric acid ethanol. After washing away excess differentiation solution with tap water, eosin staining solution was added to stain the cytoplasm for 5 minutes, and excess staining solution was washed away with tap water. After dehydration, the slides were mounted with neutral resin.

[0104] 1.4.7 Statistical Methods

[0105] Statistical analysis was performed using SPSS 25.0. Quantitative data were expressed as mean ± standard deviation (±s), and qualitative data were expressed as percentages (%). Paired-samples t-tests were used for within-group comparisons conforming to a normal distribution, and paired-samples Kruskal-Wallis tests were used for within-group comparisons not conforming to a normal distribution. Independent-samples t-tests were used for between-group comparisons conforming to a normal distribution, and Kruskal-Wallis tests or chi-square tests were used for between-group comparisons not conforming to a normal distribution. One-way ANOVA was used for comparisons among multiple groups conforming to a normal distribution, and the Kruskal-Wallis test was used for comparisons among multiple groups not conforming to a normal distribution. P < 0.05 was considered statistically significant.

[0106] 2. Results

[0107] 2.1 Effects of Examples and Comparative Examples on Skin Lesions and Pathological Manifestations in Psoriasis Model Mice

[0108] 2.1.1 Effects of the Examples and Comparative Examples on Skin Lesions in a Mouse Model of Psoriasis

[0109] Skin photographs of mice in each group after continuous administration are shown below. Figure 1 As shown. Mice in the control group had smooth, healthy pink skin without significant scaling or thickening. In contrast, mice in the model group had thickened epidermis with more erythema and scaling. Mice in Examples 1-3 had slightly reddened skin with a small amount of scaling, but this was significantly improved compared to the model group. Compared to Example 1, mice in Comparative Examples 2-3 showed more erythema and scaling. Compared to Comparative Example 1, mice in Example 1 showed less scaling.

[0110] Statistical analysis was performed on the PASI scores of dorsal skin lesions in mice of the blank group, model group, and Examples 1-3 groups on day 6 (see...). Figure 2The results showed that the compositions of Examples 1-3 improved the skin lesions on the back of psoriasis-like model mice and reduced their PASI scores.

[0111] Statistical analysis was performed on the PASI scores of dorsal skin lesions in mice of the blank group, model group, Example 1 group, and Comparative Examples 1-3 groups on day 6 (see...). Figure 3 The PASI scores of mice in Comparative Groups 1-3 were significantly different from those in Group 1 of Example 1. The results showed that the composition of Example 1 had the best effect on improving the skin lesions on the back of psoriasis-like model mice, while the PASI scores of mice in Group 1 of Example 1 were the lowest.

[0112] 2.1.2 Effects of the Examples and Comparative Examples on the Pathological Manifestations of the Psoriasis Mouse Model

[0113] Pathological examination showed that, compared with the control group, the model group mice had significantly thickened stratum corneum and epidermis, thickened spinous processes, elongated and more undulating dermal processes, loosely arranged KCs, and extensive inflammatory cell infiltration in the dermis, which are typical pathological manifestations of psoriasis. The compositions in Examples 1-3 can significantly improve the pathological manifestations of psoriasis in the model mice. Figure 4 .

[0114] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, and is not intended to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions made by those skilled in the art to the technical solution of the present invention do not depart from the essence and scope of the technical solution of the present invention.

Claims

1. A traditional Chinese medicine composition for treating psoriasis, characterized in that, The traditional Chinese medicine composition comprises, by weight, 6 parts ephedra, 9 parts cinnamon twig, 9 parts red peony root, 10 parts Japanese knotweed, 20 parts artemisia annua, and 20 parts oldenlandia diffusa; or The traditional Chinese medicine composition comprises, by weight, 1 part ephedra, 3 parts cinnamon twig, 18 parts red peony root, 20 parts Japanese knotweed, 40 parts artemisia annua, and 40 parts oldenlandia diffusa; or The traditional Chinese medicine composition consists of 12 parts ephedra, 18 parts cinnamon twig, 3 parts red peony root, 5 parts Japanese knotweed, 5 parts artemisia annua, and 5 parts oldenlandia diffusa by weight.

2. The method for preparing the traditional Chinese medicine composition according to claim 1, characterized in that, Includes the following steps: Take ephedra, cinnamon twig, red peony root, Japanese knotweed, artemisia annua, and oldenlandia diffusa and grind them into powder.

3. A drug for treating psoriasis vulgaris, characterized in that, The active ingredients of the drug include the traditional Chinese medicine composition according to claim 1 or the traditional Chinese medicine composition prepared according to the preparation method according to claim 2.

4. The use of the traditional Chinese medicine composition according to claim 1, the traditional Chinese medicine composition prepared according to the preparation method according to claim 2, or the drug for treating psoriasis vulgaris according to claim 3 in the preparation of drugs for treating psoriasis.

5. The application according to claim 4, characterized in that, The symptoms of psoriasis vulgaris include: (1) Red patches appear on the skin, covered with silvery-white scales; (2) Itching, burning or pain of the skin; (3) Dry, cracked or bleeding skin.

Images